- Oops!Something went wrong.Please try again later.
Solensia, prescribed as a once-monthly injection administered in the veterinary clinic, controls OA pain by targeting Nerve Growth Factor (NGF), a key driver in OA pain.
The drug is the first and only injectable monoclonal antibody (mAb) treatment for feline OA pain approved in the U.S.
After a single treatment, Solensia noticeably reduced OA pain. 77% of cat owners experienced seeing improvement in signs of pain after monthly treatment with Solensia in a 3-month study.
In comparison, 67% of cat owners experienced an improvement in their cat's pain signs in the placebo group.
Solensia was found to be well-tolerated: the most common side effects were vomiting and injection site pain.
Solensia is expected to be available to veterinarians in 2H of 2022. It is approved in the European Union and has been available to veterinarians since May 2021.
Price Action: ZTS shares closed lower by 2.73% at $207.00 on Thursday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.